Michael Burns BA

Michael Burns has 16 years of experience in the biotechnology field specializing in late stage process development of viral vectors. Prior to joining bluebird bio, he was the upstream lead at Amgen for the commercialization of Imlygic®(talimogene laherparepvec), the first oncolytic cancer therapy approved in the US market. Bluebird bio is in the unique position to provide several transformative gene therapies to patients, receiving both breakthrough and PRIME designations for several of their lead gene therapy programs. Michael and his team are responsible for developing the cell culture commercial vector manufacturing process for LentiGlobin®, Lenit-D™, and bb2121 (a chimeric antigen receptor targeting BCMA) at bluebird bio.